Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

llion.

"While, clearly the early part of 2009 produced disappointing clinical results for maribavir, 2008 was a very successful year for ViroPharma -- from strong financial results to great execution in all aspects of our business to the transformational acquisition of Lev Pharmaceuticals and the launch of Cinryze. As a result we believe we have positioned ourselves with a number of growth drivers and multiple opportunities for success," stated Vincent Milano, ViroPharma's president and chief executive officer. "Those who follow our company can look for a number of exciting milestones throughout the upcoming year, such as progress on Cinryze, including the ongoing commercial launch and our acute indication sBLA with a June PDUFA date; continued success with Vancocin; the planned initiation of clinical studies for NTCD; and continued strong financial performance."

Net sales of Vancocin were $50.0 million for the fourth quarter of 2008 and $232.3 million for the year ended December 31, 2008, as compared to $47.7 million and $203.8 million in the respective 2007 periods.

Operating income for the year ended December 31, 2008 was $78.7 million. Our operating loss for the fourth quarter 2008 was $3.4 million. These amounts are compared to operating income of $115.8 million and $19.0 million for the year and fourth quarter of 2007, respectively. Operating income decreased in both comparative periods primarily due to increased amortization expense, the growth in the investment in our pipeline and increased SG&A costs.

Net loss in the fourth quarter ended December 31, 2008 was $1.0 million, compared to net income of $20.4 million for the same period in 2007. For the twelve months ended December 31, 2008, net income was $67.6 million, compared to $95.4 million for the same period in 2007. Net loss per share for the quarter ended December 31, 2008 was $0.01 per share, basic and
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 Already well respected for accuracy, ... expanding its Length Gauge offerings with new variants of ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length gauge series ... Two new 1Vpp, 12mm stroke length variants of the ... is a variant with a weak spring, 0.4N of ...
(Date:2/26/2015)... Albany, NY (PRWEB) February 26, 2015 ... Market Research “Agricultural Biotechnology Market For Transgenic Crops (Corn, ... – Global Industry Analysis, Size, Share, Growth, Trends and ... valued at USD 15,300 million in 2012 and is ... at a CAGR of 9.5% from 2013 to 2019. ...
(Date:2/26/2015)... 2015 Ceres, Inc . today announced ... PartnerNetwork. In attaining Gold Level membership, Ceres has been ... knowledge in delivering Ceres, Persephone genome visualization software and ... Originally developed for in-house use by Ceres, the ... out of massive amounts of genetic data, from a ...
(Date:2/26/2015)... WOODLANDS, Texas , Feb. 26, 2015   Lexicon ... that Lexicon management will present at the Cowen 35 th ... at 8:40 a.m. EST in Boston . ... programs and milestones. A webcast of the presentation ... An archived version of the presentation will be available at ...
Breaking Biology Technology:Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... CUREXO Technology Corporation, pioneer in medical robotics and ... applications, which is focused on marketing its ROBODOC(R) ... relocating its headquarters from Sacramento to Fremont and ... executives; the remainder of the company will be ...
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) ... Term Loan and Revolving Credit Facility. Wells Fargo Foothill, ... for both the Term Loan and Revolving Credit Facility. ... loan facility of up to $10 million, and a ...
... the UK biotechnology and research services company announced ... collaboration with Novartis,to identify new drug targets and ... The collaboration combines Epistem,s stem ... into disease pathways &,bioinformatics. , ...
Cached Biology Technology:CUREXO Technology Corporation Announces New Headquarters 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4Epistem Announces Research and Development Collaboration With a Major Pharmaceutical Company 2
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... Conn. , Jan. 28, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... at the upcoming RedChip Global Online CEO Conference on ... Gino Pereira , CEO of NXT-ID ... its lead product, the Wocket smart wallet and its ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... Ariz. April 6, 2010 Scottsdale-based TGen Drug ... (GPEC) this week at BayBio2010 in an effort to ... conference April 7 in San Francisco sponsored by BayBio, ... bioscience companies, more than any other single region in ...
... study reconstructing thousands of years of fire history in the ... burns, as a tool to reduce the risk of wildfires, ... in the region,s forests. Duke University researchers used ... to more than 4,000 years ago to reconstruct the fire ...
... from the University of Cordoba (UCO) has analysed seroprevalence ... the parasite that causes toxoplasmosis in many species, including ... widespread in areas where the wild Iberian Lynx ( ... centres. Scientists are now undertaking further research into the ...
Cached Biology News:TGen Drug Development accompanies GPEC to BayBio2010 24,000-year study supports use of prescribed burns in Southern Appalachians 24,000-year study supports use of prescribed burns in Southern Appalachians 3Toxoplasma gondii spreads in the habitat of the Iberian lynx 2
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Biology Products: